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Cardiac transplantation was carried out on four patients at the
Medical College of Virginia between May and October of 1968,
in an effort to salvage them from
the terminal stages of otherwise
uncorrectable heart disease. Despite
a strikingly good early recovery
from operation in each case, three
of the patients died of acute homograft rejection in one to three
weeks; our second case is living and
well, ten months after operation,
and is at this writing the world's
third longest survivor. The world
experience to June of 1969 includes
about 130 cardiac transplants. Of
the first 100 patients operated on
over six months ago, 20 are surviving, and the majority of these
have returned to a productive existence, demonstrating the feasibility
of complete rehabilitation of at least
some terminal patients after cardiac transplantation. The high mortality rate-significantly higher than
was anticipated-has resulted from
acute and chronic homograft rejection and from the equally difficult problem of infection. Certain
lessons have been learned from our
own experience and from the world
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experience with this procedure, and
these will be reviewed in an attempt to establish the current status
and future potential of cardiac
transplantation.
Background: Animal
Experimentation

The information gained from ten
years of our laboratory experience
in part set the stage for the clinical
trials of cardiac transplantation initiated by Barnard in December of
1967. These investigations were begun first in the laboratories of Dr.
Norman E. Shumway of Stanford
University and later continued at
the Medical College of Virginia.
The feasibility of the procedure was
first established in December of
1959 when dogs were shown to recover completely after orthotopic
homotransplantation of the heart
(Lower and Shumway, 1960;
Lower, Stofer and Shumway, 1961).
The animals lived from 4 to 21
days without immunosuppressive
therapy and exhibited remarkably
normal activity until death from
rejection supervened, providing
convincing evidence that the transplanted heart could recover excellent function despite the interruption of nerves and lymphatics. In
a subsequent study two dogs recovered after transplantation of the
heart and both lungs (Lower et al.,
1961). The animals died after five
days, but showed normal ventilation and gas exchange prior to the
onset of rejection.
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Further laboratory studies
(Lower, Dong and Shumway,
1965a,b; Lower, Dong and Glazener, 1966) revealed that the most
sensitive and reliable test for impending cardiac rejection was a fall
in the QRS voltage on the electrocardiogram, often with the additional finding of abnormal intraventricular conduction. With the
advent of immunosuppressive
drugs, specifically azathioprine and
methylprednisolone, survival of animals was prolonged by treating
each recognized rejection crisis
with transiently high doses of the
drugs which were then tapered to
lower maintenance doses in an attempt to diminish the high incidence of toxicity and infection. A
few animals survived more than a
year and provided a significant
stimulus to the subsequent clinical
application of cardiac transplantation. Extensive physiologic tests of
the transplanted heart revealed that,
although function was often depressed for the first 24 to 48 hours,
thereafter cardiac output, even in
response to stress, was remarkably
adequate (Dong et al., 1965). In
some animals made to breathe 7 %
oxygen, cardiac outputs could be
markedly increased (Kontos and
Lower, 1969).
Evidence of autonomic reinnervation was seen in the majority of
transplants within a few months after operation and was confirmed
by appropriate immediate responses
to direct electrical stimulation of
vagal and sympathetic nerves
(H. A. Kontos, M. D. Thames
and R. R. Lower, unpublished
data). The return of sinus arrhythmia was also seen as a useful indicator of vagal reinnervation
(Thames, Kontos and Lower,
1969), and the ability of the heart
to respond reflexly to peripheral hypertension also reappeared (H. A.
Kontos et al., unpublished data).
Recently, fluorescent staining of
sympathetic fibers has confirmed
their regeneration within the graft
after several months.+
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tered considerable enthusiasm concerning the application of cardiac
transplantation to human disease,
this enthusiasm was tempered by
certain additional observations. In
about 25 % to 30 % of acute rejection crises, it was difficult or impossible to control the rejection process with drugs. Where continuous
or high dose immunosuppression
was needed, infection was often inevitable. Moreover, on histologic
examination of animals surviving
over three months, all showed some
evidence of compromise of coronary arterial lumens by thickening of the intimal layer. In some
of the longest surviving cases a few
of the coronary arteries were nearly
occluded. These findings were presented in 1967 (Lower and Cleveland, 1968), but it was out hope
that improved methods of histocompatibility matching along with
better drugs for immunosuppression, such as antilymphocyte globulin, might make cardiac transplantation in man less susceptible
to both acute and chronic rejection. Unfortunately these aims have
not been entirely realized.
Selection of Recipients
and Donors
The selection of patients for
cardiac transplantation has generally been reserved for those in the
terminal stage of their illness with
no alternative hope for recovery.
This policy is attested to by the
large numbers of patients who have
died in our hospital and elsewhere
while awaiting a suitable heart
donor. In the Stanford series, for
example, the mean survival of patients accepted for transplantation,
but for whom no suitable donor
could be obtained, has been four
weeks, with a maximal survival of
12 weeks (N. E. Shumway, personal communication).

:j: Studies performed by Dr. John E.
Norvell, Department of Anatomy,
Medical College of Virginia.

Two of our patients had sustained multiple myocardial infarctions with the subsequent development of refractory heart failure.
The other two patients had cardiomyopathy of undetermined etiology
with severe biventricular failure.
Cardiac catheterization in each case
revealed pulmonary hypertension,
elevation of the left ventricular end
diastolic pressure, low cardiac output and extremely poor contractility of the left ventricle. The patients
were all considered to have no alternative hope for recovery from
their cardiac disease and were,
therefore, accepted for cardiac
transplantation.
The selection of donors required
the establishment of irretrievable
brain death by an independent
team of neurosurgeons and neurologists. Brain death in these cases
was caused by extensive intracerebral hemorrhage or by massive
brain trauma. The criteria included
no pupillary reaction, absence of
spontaneous respiration or movements, absence of reflexes and an
isoelectric electroencephalogram.
The heart in the donor invariably
required vasopressors for support
and had usually sustained one or
more episodes of arrest. It is of
interest that, despite its failing
status in the donor, the heart in
each case adequately supported the
circulation in the recipient as soon
as coronary blood flow was reestablished.
Prospective histocompatibility
typing by the microlymphocytotoxicity techniques of Terasaki was
carried out in each case. However,
despite an excellent match with no
demonstrable major incompatibility
in the first case, the patient died of
acute fulminating rejection at one
week and was the first patient in
the world experience to die from
this cause. The course in this patient illustrated that typing, as current y practised, does not in fact
detect, with sufficient sensitivity,
all forms of incompatibility. The
second patient, however, was also
an excellent match; and, although
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he has sustained three rejection episodes, each one responded well to
a temporary increase in immunosuppressive therapy, and he remains well.
The third patient in this series
demonstrated a principle which
may continue to receive increased
attention in the preoperative matchings of potential recipients. Despite
the absence of preformed antibodies detected by the routine preoperative serum-lymphocyte cross
match, retrospective studies of the
patient's serum by the technique of
immune adherence established that
some degree of prior sensitization
did exist, as antibodies were present
against cultured kidney cells from
the same donor. The patient's clinical course was characterized by a
fulminating rejection episode at one
week which was unresponsive to
massive immunosuppressive therapy. The fourth patient, mismatched for histocompatibility antigen HLA-3, initially responded to
therapy for a rejection episode at
one week, but subsequently became
refractory to treatment and died of
rejection at 18 days. Antibody was
eluted from the heart postmortem
in each of the three fatal cases. The
possible role of antibody in acute
cardiac rejection has been discussed
further in another report (G. M.
Williams et al., unpublished data).
Surgical Techniq ue

The basic surgical technique
which proved successful in animal
transplantation (Lower et al.,
1961) was employed in our own
cases and has been generally utilized
by other transplant surgeons with
few modifications. The posterior
atrial wall, containing the openings
of the vena cavae and pulmonary
veins, is retained in the recipient to
facilitate anastomosis of the donor
heart. Anastomosis of the aorta
and pulmonary artery in the supravalvular region completes the procedure. Surgeons have varied most
in their management of the donor
heart. In our own cases the donor

heart was cooled by immersion in
saline at 8 to 10 C to afford the
myocardium protection during the
60 to 90 minutes that coronary circulation was interrupted and no
coronary perfusion was used.

most useful in the treatment of a
difficult rejection crisis or where
there are wide histocompatibility
differences.

Postopera tive Management

The early detection of a rejection
crisis requires close monitoring of
the electrocardiogram on at least a
daily basis for the first few months.
The primary signs of impending
rejection are a decrease in the QRS
voltage, a rightward shift in the
frontal plane axis, delayed intraventricular conduction and atrial or
nodal arrhythmias. Rejection is
characterized clinically by the insidious onset of right heart failure
as evidenced by weight gain, edema,
venous distention with increased
pulsations, right ventricular gallop,
and, eventually, the development of
murmurs of relative tricuspid or
mitral insufficiency. Early in the
course of rejection the lung fields
appear radiographically clear and
even oligemic, in reflecting the predominant right heart failure. Thus,
it is suggested that digitalis preparations and diuretics be discontinued as soon as is practical after
operation to avoid masking this important collateral evidence of impending rejection.
While serum enzyme abnormalities do occur with some rejection
episodes (particularly elevation of
the lactic dehydrogenase isozymes I
and II and the creatine phosphokinase), these abnormalities occur as
a late manifestation of rejection
and indicate a more severe degree
of myocardial injury. It is apparent
from our own observations and the
experience of others that a typical
rejection crisis can occur and be
diagnosed by other clinical and
ECG criteria without detectable abnormalities in the serum enzymes.
However, enzyme levels were
markedly elevated in the terminal
stages of each of the fatal rejection
episodes in our patients.
The other nonspecific signs and
symptoms occurring in conjunction
with rejection, such as pericardia!

Postoperative management of the
recipient has varied little from the
care of the routine cardiac surgery
patient with the exceptions that immunosuppressive therapy is administered in an effort to prevent rejection, and monitoring efforts are
directed toward the early detection
of a rejection crisis (Lower et al.,
1968; Sewell, Kemp and Lower,
1969). It now seems apparent that
the cardiac transplant recipient has
an immunologic capability that is
less impaired than the chronically
uremic renal transplant patient, and
the cardiac patient, therefore, requires more intensive immunosuppression, at least in the initial weeks,
to control rejection. This was not
appreciated early in our experience
but has evolved as the world results
have been discussed. The current
recommendations which have received widest acceptance are that
the recipient be given azathioprine
in the largest dose tolerated, usually
3 to 4 mg/ kg, and prednisone in a
dose of 200 mg/ day during the
initial two to three weeks. Drugs
are later tapered to a lower maintenance dose to decrease the risk of
infection and the other side effects
of steroid administration.
The role of antilymphocyte globulin is less clearly established. Some
patients have been managed successfully without it; others have developed fatal, acute or chronic rejection despite its use. The optimal
preparation, route of administration and dose have not been agreed
upon. Some patients reportedly
have rapidly developed antibodies
against the horse globulin with evidence that its immunologic effectiveness is rapidly dissipated (Butler et al., 1969). A few investigators have therefore considered it

Early Detection of Rejection

169

R. R. LOWER ET AL.
friction rub, fever, leukocytosis and
malaise, can all occur with other
postoperative complications, e.g.,
infection, embolism or the various
post-perfusion syndromes, and are
thus of limited value in the diagnosis of impending rejection.

populated by host cells has yet to
be established . More precise histocompatibility matching and more
effective immunosuppression would
at the moment seem to offer the
best insurance against loss of the
graft due to chronic rejection.

Treatment of Acute Rejection
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